Weighing up the evidence

Article Abstract:

A meta-analysis of the clinical trials of rosiglitazone, which is marketed under the name Avandia by GlaxoSmithKline (GSK), has found that the chances of cardiovascular risks is higher in patients taking the drug than in those not taking this drug. The impact of this meta-analysis on the fate of Avandia and the patients is discussed.

Product development, Pharmaceutical Preparation Manufacturing, Antidiabetic Preparations, Complications and side effects, Hypoglycemic agents, Avandia (Medication), GlaxoSmithKline PLC

---

Cheap at any price?

Article Abstract:

Acquisitions have become very common in pharmaceutical companies in order to replenish their drug pipelines and strengthen their standing in biotechnology. AstraZeneca's purchase of MedImmune, a Maryland biotechnology company, is one of the latest in the string of acquisitions.

Acquisitions & mergers, United States, Mergers, acquisitions and divestments, Company acquisition/merger, AstraZeneca PLC, MedImmune Inc., AZN

---

Similar abstracts:

• Abstracts: Brute force in the clinic. The heart of the cycle
• Abstracts: Challengers in the field. More fizz at Pfizer? Swiss star finds it tough at the top
• Abstracts: Getting in the frame. A new silver age? Passive-smoking study faces review
• Abstracts: Understanding the valency of rare earths from first-principles theory. Magnetic trapping of rare-earth atoms at millikelvin temperatures
• Abstracts: Lie back and think of science. Catch a falling star. Buried treasure

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.